Company Profile

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/09/26	$0.6341	+11.23%	303,561
15/09/26	$0.5701	-9.91%	402,557
14/09/26	$0.6328	-4.16%	404,676
11/09/26	$0.6603	-5.77%	294,293
10/09/26	$0.7007	-0.04%	208,007

Delayed Quote Nasdaq

More quotes

Market Closed - Nasdaq 23:00:00 17/09/2026 +03			5-day change	1st Jan Change
0.6341 ^USD	+9.16%		-9.50%	-65.35%

08-14	Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT

Markets		Quality
Nasdaq	JSPR	Delayed
CBOE	JSPR	Real-time

08-14	Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
08-05	Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors	CI
07-17	Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026	CI
07-17	Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall	MT
07-16	Kira Pharmaceuticals acquired Jasper Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.	CI
07-16	Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding	CI
06-02	Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value	CI
06-01	Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives	MT
05-21	Jasper Therapeutics, Inc. Announces Board and Board Committee Changes	CI
05-15	RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk	MT
05-15	TD Cowen Downgrades Jasper Therapeutics to Hold From Buy	MT
05-14	Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
05-15	RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk	MT
05-15	TD Cowen Downgrades Jasper Therapeutics to Hold From Buy	MT
03-23	UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25	MT
11-11	RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk	MT

Kira Pharmaceuticals Stock

Stocks

JSPR

US4718712023

Biotechnology & Medical Research

Chart: Kira Pharmaceuticals

Latest news: Kira Pharmaceuticals

Last Transcript: Kira Pharmaceuticals

Analysts' recommendations: Kira Pharmaceuticals

Press Releases: Kira Pharmaceuticals

News in other languages: Kira Pharmaceuticals

Quotes and Performance

Price Extremes

Managers and Directors: Kira Pharmaceuticals

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Quotes

09-15	Jasper Therapeutics Announces Key Regulatory and Clinical Appointments	AQ
09-09	Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-17	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
08-14	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
07-17	Jasper Therapeutics Announces Merger with Kira Pharmaceuticals	AQ

19/09/25	USA-Les valeurs à suivre à Wall Street (actualisé)
16/11/21	MÄRKTE USA/Kaum verändert - Zwischen China-Hoffnung und Zinssorgen
15/11/21	MÄRKTE USA/Wall Street dreht leicht ins Minus
15/11/21	MÄRKTE USA/Wall Street mit Vorschusslorbeeren für Biden-Xi-Gipfel
15/11/21	MÄRKTE USA/Wall Street vor Biden-Xi-Gipfel leicht optimistisch

1 week	0.57	0.67
1 month	0.57	0.81
Current year	0.55	1.03
1 year	0.55	1.03
3 years	0.55	1.03
5 years	0.55	1.03
10 years	0.55	1.03

Manager	Title	Age	Since
Jeet Mahal CEO	Chief Executive Officer	54	06/01/2026
Herbert Cross DFI	Director of Finance/CFO	54	22/09/2023
Matthew Ros COO	Chief Operating Officer	59	16/07/2026

Director	Title	Age	Since
Jeet Mahal BRD	Director/Board Member	54	06/01/2026
Judith Shizuru BRD	Director/Board Member	70	04/09/2021
Kurt von Emster BRD	Director/Board Member	58	24/09/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/31/26 A	Judith Shizuru	Free	Founder	7,500	0.0267%
7/31/26 A	Patrick Crutcher	Free	Director	7,500	0.0267%
7/31/26 A	Thomas Wiggans	Free	Chairman	7,500	0.0267%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KIRA PHARMACEUTICALS	+9.16%	-9.50%	-	-	19.33M
WUXI APPTEC CO., LTD.	+1.76%	+3.88%	+46.85%	+101.12%	70.89B
ARGENX SE	+0.83%	+2.48%	+41.49%	+79.23%	62.32B
INSMED INCORPORATED	+1.14%	-2.59%	-14.37%	+365.92%	27.07B
BIONTECH SE	+2.95%	+2.34%	+0.52%	-12.74%	24.78B
GENMAB A/S	+1.43%	+8.80%	+28.12%	-12.56%	20.59B
PHARMAESSENTIA CORPORATION	-0.83%	-9.47%	+174.16%	+295.44%	15.52B
EXELIXIS, INC.	+3.01%	+1.85%	+44.63%	+168.18%	14.49B
SUMMIT THERAPEUTICS INC.	+2.43%	+4.24%	-2.05%	+847.59%	14.14B
MADRIGAL PHARMACEUTICALS, INC.	+1.00%	+0.24%	+28.02%	+203.83%	12.35B
Average	+2.29%	+1.64%	+38.60%	+226.22%	29.13B
Weighted average by Cap.	+1.48%	+2.50%	+37.30%	+163.87%